



SAFETY DATA SHEET

Revision date: 05-May-2015

Version: 2.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Ziprasidone Hydrochloride Capsules (Greenstone LLC)

Trade Name: Not applicable

Chemical Family: Benzisothiazol derivative

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antipsychotic

Details of the Supplier of the Safety Data Sheet

Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Skin Sensitization: Category 1

Specific target organ systemic toxicity (repeated exposure): Category 2

EU Classification:

EU Indication of danger: Irritant
Harmful

EU Risk Phrases:

R43 - May cause sensitization by skin contact.

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Label Elements

Signal Word: Warning

Hazard Statements: H317 - May cause an allergic skin reaction
H373 - May cause damage to organs through prolonged or repeated exposure

Precautionary Statements: P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P272 - Contaminated work clothing should not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P314 - Get medical attention/advice if you feel unwell
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental first aid instructions on this label)
P363 - Wash contaminated clothing before reuse
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 2 of 9

Version: 2.0



Other Hazards

No data available

Australian Hazard Classification (NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Additional Information:

For a more detailed discussion of potential health hazards and toxicity see Section 11.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Ziprasidone hydrochloride	138982-67-9	Not Listed	Xi;R43 Xn;R48/22	Skin Sens.1 (H317) STOT RE.2 (H373)	22-30
Starch, pregelatinized	9005-25-8	232-679-6	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Hard gelatin capsules	MIXTURE	Not Listed	Not Listed	Not Listed	*
Lactose NF, monohydrate	64044-51-5	Not Listed	Not Listed	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 3 of 9

Version: 2.0

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Additional Information: This material is not expected to support combustion

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 4 of 9

Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Ziprasidone hydrochloride

Manufacturer OEL: 90ug/m³, Sensitizer

Starch, pregelatinized

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 5 of 9

Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	Color:	20 mg (blue/white), 40 mg (blue/blue), 60 mg (white/white), and 80 mg (blue/white)
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
Ziprasidone hydrochloride			
Measured Log P	3.44		
Hard gelatin capsules			
No data available			
Starch, pregelatinized			
No data available			
Lactose NF, monohydrate			
No data available			
Magnesium stearate			
No data available			
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		
Relative Density:	No data available		
Viscosity:	No data available		
Flammability:			
Autoignition Temperature (Solid) (°C):		No data available	
Flammability (Solids):		No data available	
Flash Point (Liquid) (°C):		No data available	
Upper Explosive Limits (Liquid) (% by Vol.):		No data available	
Lower Explosive Limits (Liquid) (% by Vol.):		No data available	
Polymerization:		Will not occur	

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 6 of 9

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Short Term:

Antipsychotic drug: causes central nervous system effects

Known Clinical Effects:

Adverse effects associated with therapeutic use include sleepiness (somnolence), tiredness, nausea, constipation, dizziness, restlessness, jerky muscle movement, diarrhea, and skin rash.

Acute Toxicity: (Species, Route, End Point, Dose)

Ziprasidone hydrochloride

Rat Oral LD50 > 2000 mg/kg
Rat IP LD50 > 2000mg/kg
Mouse Oral LD50 > 2000mg/kg
Mouse IP LD50 500-1000mg/kg
Rabbit Dermal LD50 > 2000mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Ziprasidone hydrochloride

Eye Irritation Rabbit Non-irritating
Skin Irritation Rabbit Non-irritating
Skin Sensitization - GPMT Guinea Pig Positive

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ziprasidone hydrochloride

6 Month(s) Rat Oral 40 mg/kg/day LOAEL Central nervous system, Liver
6 Month(s) Dog Oral 40 mg/kg/day LOAEL Central Nervous System, Liver
1 Month(s) Rat Oral 160 mg/kg/day NOAEL Central Nervous System
12 Month(s) Dog Oral 10 mg/kg/day NOAEL Central Nervous System

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ziprasidone hydrochloride

Reproductive & Fertility Rat Oral 40 mg/kg/day NOAEL Negative
Peri-/Postnatal Development Rat 5 mg/kg/day NOAEL Embryotoxicity, Fetotoxicity
Embryo / Fetal Development Rat Oral 10 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 30 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ziprasidone hydrochloride

In Vitro Human Lymphocytes Negative
In Vivo Mouse Bone Marrow Negative

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 7 of 9

Version: 2.0

11. TOXICOLOGICAL INFORMATION

In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ziprasidone hydrochloride

2 Year(s) Rat Oral 12 mg/kg/day Not carcinogenic
2 Year(s) Mouse Oral 200 mg/kg/day Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: The active ingredient in this mixture was not acutely toxic to aquatic organisms at its maximum solubility. See aquatic toxicity data below.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ziprasidone hydrochloride

Daphnia magna (Water Flea) OECD EC50 48 Hours > 0.048 mg/L
Pimephales promelas (Fathead Minnow) TAD LC50 96 Hours > 0.035 mg/L
Selenastrum capricornutum (Green Alga) OECD ErC50 72 Hours > 0.12 mg/L
Daphnia magna (Water Flea) OECD NOEC 21 Days 0.005 mg/L
Ceriodaphnia dubia (Daphnids) OECD NOEC 7 Days 0.021 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Ziprasidone hydrochloride

Activated sludge OECD EC50 > 1000 mg/L

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Ziprasidone hydrochloride Ready 36% After 28 Day(s) Not Ready

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Ziprasidone hydrochloride

Measured Log P 3.44

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 8 of 9

Version: 2.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



Hard gelatin capsules

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Ziprasidone hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Starch, pregelatinized

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

SAFETY DATA SHEET

Material Name: Ziprasidone Hydrochloride Capsules
(Greenstone LLC)
Revision date: 05-May-2015

Page 9 of 9

Version: 2.0

15. REGULATORY INFORMATION

Lactose NF, monohydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	Not Listed

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure

Xn - Harmful
Xi - Irritant

R43 - May cause sensitization by skin contact.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 05-May-2015
Product Stewardship Hazard Communication

Prepared by: Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet